Rezūm™: yay or nay? From the patients’ perspective: a patient reported outcome measure (PROM) study from a single UK centre

Background: RezūmTM steam ablation therapy is an effective minimally invasive surgical therapy for the treatment of symptomatic benign prostatic hyperplasia. The aim of this study was to assess the perception of this treatment from the patients’ perspective at a single centre.
Methods: A patient reported outcome measure (PROM) questionnaire was sent to 65 consecutive patients at least 6 months after undergoing RezūmTM therapy. We evaluated changes in their prostate symptoms, quality of life (QoL) as well as new onset sexual dysfunction.
Results: A total of 44 questionnaires were analysed with a response rate of 67.7%. Mean prostate volume was 62 mL in a mean population age of 68 years. There was a significant improvement in mean International Prostate Symptom Score and QoL scores (P < 0.0001). There was a higher rate of de novo sexual dysfunction noted as compared to other studies. Retreatment procedures occurred in 4.3% of patients, whilst 88.9% reported being medication free. Thirty-five (79.5%) respondents will recommend the procedure.
Conclusions: This study highlighted that the beneficial effects of RezūmTM observed clinically were also perceived positively by patients in a real-world setting, which is just as equally important.